First patient dosed in Ph 1/2 study of Silmitasertib in children and young adults with R/R solid tumors November 12, 2024
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize SC ENHERTU® Enabled by Alteogen’s Hybrozyme™ Technology November 12, 2024
Positive TNG462 Clinical Data reported and Update provided on PRMT5 Development Program November 12, 2024
Applications submitted in the U.S. and EU seeking approval of DARZALEX FASPRO / DARZALEX as SC monotherapy for high-risk smoldering multiple myeloma November 12, 2024
FDA approved obecabtagene autoleucel (Aucatzyl) for adults with R/R B-cell precursor acute lymphoblastic leukemia (ALL) November 12, 2024
Orphan Drug Designation from the US FDA for LBL-034 for the Treatment of Multiple Myeloma November 12, 2024
Orphan Drug Designation by US FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma November 12, 2024
NDA Submitted to the U.S. FDA for Sunvozertinib in Treating R/R NSCLC with EGFR Exon 20 Insertion Mutations November 12, 2024
MHRA grants marketing authorisation for BALVERSA (erdafitinib) for PD-(L)1 inhibitor-treated adults with unresectable/metastatic urothelial carcinoma (UC) with FGFR3 alterations November 12, 2024
